{"schema":"sb.node.v1","id":"sb:e/835b5dfbcddf4005d622ae55","kind":"entity","label":{"text":"t-cell","locale":"en"},"identity":{"anchor":"label:en:t-cell","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-06T17:33:03.396507+00:00","snapshot":"deploy b18bf6491b6a7c86d8f2e23bc6c6d7a2a87538df"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":113,"separatePublishers":37,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-01-01","to":"2026-10-05","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.142: about 86% of mentions carry no typed assertion"]}},"dimensions":{"domains":["precision_medicine","auto","pubmed_targeted"],"activeDays":37,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/ffe356a3f8154927f05349cf","kind":"observation","label":"Pulse 2.0 · 2026-10-03 · Novartis Signs Up To $7.8 Billion Licensing Deal With Abogen For mRNA-Encoded T-Cell Engager","url":"https://pulse2.com/novartis-signs-up-to-7-8-billion-licensing-deal-with-abogen-for-mrna-encoded-t-cell-engager/"},{"id":"sb:o/aed01b0b5b43240d88840443","kind":"observation","label":"J Immunother Cancer · 2026-10-01 · Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer.","url":"https://doi.org/10.1136/jitc-2026-015279"},{"id":"sb:o/7dcb2e4169f67b3a884477a8","kind":"observation","label":"bioRxiv Cancer Biology · 2026-09-28 · Spatial immune profiling reveals lymphocyte confinement to myeloid-mesenchymal niches and heterogeneous therapeutic T-cell opportunity in pediatric ependymoma","url":"https://www.biorxiv.org/content/10.64898/2026.09.24.754209v1?rss=1"},{"id":"sb:o/b99f6567b0275215576a0627","kind":"observation","label":"Br J Pharmacol · 2026-09-28 · Low-dose antiangiogenic multikinase inhibitor AL3810 synergizes with PD-1 blockade by reducing CSF1-driven MHC-IIint tumour-associated macrophages to optimize TIM-3+ CD8…","url":"https://doi.org/10.1111/bph.70664"},{"id":"sb:o/2bf1b85d0d7ee7e588e1b355","kind":"observation","label":"European Medical Journal · 2026-09-24 · Fatal Inflammatory Risks Associated with CAR T-Cell Therapy","url":"https://www.emjreviews.com/rheumatology/news/fatal-inflammatory-risks-associated-with-car-t-cell-therapy/"},{"id":"sb:o/d2e7022309f8e2b8a74daf48","kind":"observation","label":"CRC Research (Google News) via Google News · 2026-09-23 · CAR T-Cell Therapy Takes a New Step in Colorectal Cancer – Colorectal Cancer Alliance - Oncodaily","url":""},{"id":"sb:o/175c7f373d0351535795e6a6","kind":"observation","label":"BMJ Oncol · 2026-09-21 · Cytotoxic T-cell exhaustion analyses by in situ single-cell immunofluorescence in relation to colorectal cancer patient age, tissue bacteria and mortality.","url":"https://doi.org/10.1136/bmjonc-2026-001159"},{"id":"sb:o/d2e7022309f8e2b8a74daf48","kind":"observation","label":"CRC Research (Google News) via Google News · 2026-09-17 · FDA Clears a New CAR T-Cell Therapy Trial to Fight Colorectal Cancer – CU Anschutz - Oncodaily","url":""},{"id":"sb:o/12a07f4e969572d13c93d65f","kind":"observation","label":"J Immunother Cancer · 2026-09-12 · Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance.","url":"https://doi.org/10.1136/jitc-2026-015228"},{"id":"sb:o/c9cf9e64faf945ece8c2ef3d","kind":"observation","label":"Fierce Biotech · 2026-09-03 · AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial","url":"https://www.fiercebiotech.com/biotech/abbvies-bispecific-t-cell-engager-shows-promise-ph-3-multiple-myeloma-trial"}],"cursor":"c1.eyJpZCI6InNiOmUvODM1YjVkZmJjZGRmNDAwNWQ2MjJhZTU1IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA2VDE3OjMzOjAzLjM5NjUwNyswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":11,"byKind":{"claim":1,"co-mentioned":10},"items":[{"id":"sb:p/467f407a99839c93f45d014f","kind":"claim","label":"Propionate promotes CD8+ T-cell infiltration and enhances immunotherapy efficacy in colorectal cancer — single source","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with immunotherapy (56 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/90bb905c886825b7846113cc"},{"kind":"relation","label":"co-mentioned with car-t (39 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f1006b5a34579889c60a7077"},{"kind":"relation","label":"co-mentioned with fda (37 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/dcad2a4c6059a3272d4d7ea6"},{"kind":"relation","label":"co-mentioned with ai (35 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2795b6c06ccf23f30253fab1"},{"kind":"relation","label":"co-mentioned with colorectal cancer (35 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/fd16f273da5c77a6abc1331e"},{"kind":"relation","label":"co-mentioned with clinical trial (25 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/61fe2ba3e8864005ae17247e"},{"kind":"relation","label":"co-mentioned with solid tumors (23 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/6554cd5d7abdd9a0edba9742"},{"kind":"relation","label":"co-mentioned with united states (23 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b497a0fdb8b7bc1469c98d84"},{"kind":"relation","label":"co-mentioned with lung cancer (22 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8529a99fa9bb5b4bee98854c"}],"cursor":"c1.eyJpZCI6InNiOmUvODM1YjVkZmJjZGRmNDAwNWQ2MjJhZTU1IiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0wNlQxNzozMzowMy4zOTY1MDcrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/835b5dfbcddf4005d622ae55","mcp":"traverse {\"id\":\"sb:e/835b5dfbcddf4005d622ae55\"}","page":"/entity/t-cell/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/835b5dfbcddf4005d622ae55\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/835b5dfbcddf4005d622ae55\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/835b5dfbcddf4005d622ae55\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/835b5dfbcddf4005d622ae55\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}